About: Surfactant therapy for acute respiratory failure in children: a systematic review and meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Surfactant therapy for acute respiratory failure in children: a systematic review and meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Surfactant therapy for acute respiratory failure in children: a systematic review and meta-analysis
Creator	Ng, Vivian Cook, Deborah Randolph, Adrienne Choong, Karen Duffett, Mark
Source	PMC
abstract	INTRODUCTION: Exogenous surfactant is used to treat acute respiratory failure in children, although the benefits and harms in this setting are not clear. The objective of the present systematic review is to assess the effect of exogenous pulmonary surfactant on all-cause mortality in children mechanically ventilated for acute respiratory failure. METHODS: We searched the MEDLINE, EMBASE, CINAHL and Ovid Healthstar databases, the bibliographies of included trials and review articles, conference proceedings and trial registries. We included prospective, randomized, controlled trials of pulmonary surfactant that enrolled intubated and mechanically ventilated children with acute respiratory failure. We excluded trials that exclusively enrolled neonates or patients with asthma. Two reviewers independently rated trials for inclusion, extracted data and assessed the methodologic quality. We quantitatively pooled the results of trials, where suitable, using a random effects model. RESULTS: Six trials randomizing 314 patients were included. Surfactant use reduced mortality (relative risk = 0.7, 95% confidence interval = 0.4 to 0.97, P = 0.04), was associated with increased ventilator-free days (weighted mean difference = 2.5 days, 95% confidence interval = 0.3 to 4.6 days, P = 0.02) and reduced the duration of ventilation (weighted mean difference = 2.3 days, 95% confidence interval = 0.1 to 4.4 days, P = 0.04). CONCLUSION: Surfactant use decreased mortality, was associated with more ventilator-free days and reduced the duration of ventilation. No serious adverse events were reported.
has issue date	2007-06-15(xsd:dateTime)
bibo:doi	10.1186/cc5944
bibo:pmid	17573963
has license	cc-by
sha1sum (hex)	d68d71553d3a31381c0c3851351f912a9a7be1c9
schema:url	https://doi.org/10.1186/cc5944
resource representing a document's title	Surfactant therapy for acute respiratory failure in children: a systematic review and meta-analysis
has PubMed Central identifier	PMC2206432
has PubMed identifier	17573963
schema:publication	Crit Care
resource representing a document's body	covid:d68d71553d3a31381c0c3851351f912a9a7be1c9#body_text
is schema:about of	named entity 'acute respiratory failure' named entity 'PRESENT' named entity 'ACUTE RESPIRATORY FAILURE' named entity 'PULMONARY SURFACTANT' named entity 'SYSTEMATIC REVIEW' named entity 'INTRODUCTION' covid:arg/d68d71553d3a31381c0c3851351f912a9a7be1c9 named entity 'adverse events' named entity '4.2' named entity 'hospital discharge' named entity 'surfactants' named entity 'ALI' named entity 'acute respiratory failure' named entity 'ventilator' named entity 'mechanical ventilation' named entity 'mechanical ventilation' named entity 'Acute Lung Injury' named entity 'high-frequency oscillatory ventilation' named entity 'nitric oxide' named entity 'hypotension' named entity 'adverse events' named entity 'intubated' named entity 'statistically significant' named entity '95% CI' named entity 'assess' named entity 'surfactant' named entity 'Surfactant' named entity 'WMD' named entity '95% confidence interval' named entity 'acute respiratory failure' named entity 'critically ill' named entity 'PICU' named entity 'surfactant' named entity 'high-frequency oscillatory ventilation' named entity 'respiratory syncytial virus' named entity 'Acute respiratory failure' named entity 'mechanically ventilated' named entity '1.1' named entity 'endotracheal tube' named entity 'Surfactant' named entity 'control groups' named entity 'acute respiratory failure' named entity '95% CI' named entity 'arterial oxygen tension' named entity 'PICU' named entity 'respiratory failure' named entity 'meta-analysis' named entity 'pulmonary surfactant' named entity 'systematic review' named entity 'mechanical ventilation' named entity 'ARDS' named entity 'phospholipids' named entity 'allocation concealment' named entity 'randomized controlled trials' named entity 'surfactant' named entity 'morbidity' named entity 'protein' named entity 'random effects model' named entity 'RSV' named entity 'surfactant' named entity 'bronchiolitis' named entity 'extracorporeal membrane oxygenation' named entity 'Meta-analysis' named entity 'confidence interval' named entity 'surfactants' named entity 'surfactant' named entity 'mechanical ventilation' named entity 'confidence interval' named entity 'ventilator' named entity 'Pediatric' named entity 'statistically significant' named entity 'ventilator' named entity 'ventilator' named entity 'mechanical ventilation' named entity 'endogenous' named entity 'surfactant' named entity 'acute respiratory distress syndrome'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software